Core Viewpoint - The healthcare and biotechnology sectors in the Hong Kong stock market have shown significant positive performance, with various indices reflecting substantial gains as of the midday close. Group 1: Index Performance - The CSI Hong Kong Stock Connect Healthcare Comprehensive Index increased by 4.0% [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 3.7% [1] - The CSI Innovative Drug Industry Index saw a rise of 3.3% [1] - The CSI Biotechnology Theme Index increased by 2.8% [1] - The CSI 300 Healthcare Index rose by 2.1% [1] - The Hang Seng Innovative Drug ETF (159316) recorded a trading volume exceeding 500 million yuan [1] Group 2: ETF and Index Details - The Biotechnology ETF (159837) tracks the CSI Biotechnology Theme Index, which focuses on A-share biotechnology leaders and has a rolling P/E ratio of 60.7 times, with a 2.8% increase [4] - The CSI 300 Healthcare Index ETF (512010) tracks the CSI 300 Healthcare Index, covering major companies in the healthcare sector, with a rolling P/E ratio of 32.8 times and a 2.1% increase [4] - The indices have been established for several years, with the CSI Biotechnology Theme Index launched in 2015 and the CSI 300 Healthcare Index in 2007 [5]
港股医药板块领涨，恒生创新药ETF（159316）交投活跃，半日成交额超5亿元
Mei Ri Jing Ji Xin Wen·2025-09-01 05:01